🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are excited to announce that the FDA has granted Breakthrough Therapy designation for felzartamab for primary membranous nephropathy! Learn more about this important step forward: hibio.com/news/hi-bio-an…

We enjoyed attending American Society of Nephrology’s annual Kidney Week meeting, where we presented final Phase 2 M-PLACE data. Thanks to our collaborators, advisors and everyone who made the event possible. You can read our posters and presentations from the meeting here: hibio.com/science#public…

Today, we’re pleased to announce our $95 million Series B to advance targeted therapies for immune-mediated diseases – bringing felzartamab, our clinically differentiated lead candidate, through clinical readouts and preparation for registrational studies. hibio.com/news/hi-bio-an…

We are excited to announce that the FDA has granted orphan drug designation for felzartamab, our investigational agent in development for the treatment of antibody-mediated rejection in kidney transplant recipients! More on this important step here: hibio.com/news/hi-bio-re…

Today is IgAN Awareness Day! IgAN is a serious, rare kidney disease, impacting more than 130,000 patients in the U.S. today. We're proud to work with investigators to advance therapies for patients in need. Thanks to the @IgANFoundation for their work! #IgANAware

Today we announced a definitive agreement under which Biogen has agreed to acquire HI-Bio. The proposed acquisition combines expertise in immune-mediated indications with global development and commercial experience in rare diseases. Read more: hibio.com/news/biogen-bo…

This weekend, our team attended the AmericanTransplantCongress to further discuss the recent positive felzartamab data in antibody-mediated rejection (AMR) in kidney transplant recipients recently featured in NEJM. View the presentation here: assets.hibio.com/undefined/fina… #ATC2024Philly

The acquisition of HI-Bio by Biogen has been completed. Together, we will be advancing our clinical development plans to deliver innovative treatments to patients in need. Follow @Biogen for the latest news and read about the acquisition: investors.biogen.com/news-releases/…